Pharma Journalist -

Agenus Inc. announced that the first patient has been dosed in a Phase 1/2 clinical trial of its anti-PD-1 antibody, AGEN2034. The open-label, dose-escalation portion of the trial is…
Read More...

uniQure N.V. announced that it will not pursue the renewal of the Glybera (alipogene tiparvovec) marketing authorization in Europe when it is scheduled to expire on October 25, 2017.…
Read More...

H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology…
Read More...

Sawai Pharmaceutical Co. Ltd., a leading Japanese generic pharmaceuticals manufacturer, and Upsher-Smith Laboratories, Inc., ("Upsher-Smith"), an established generics manufacturer based…
Read More...

ReForm Biologics, a pharmaceutical technology company that develops proprietary excipients to improve biologic formulations, announced that the Company’s Board of Directors has…
Read More...

A certified CDISC provider and leader in pharmacometrics, Certara has developed a new solution which will enable sponsors to achieve new compliance requirements effortlessly
Read More...

Veeva Systems announced Veeva Vault SiteExchange, a cloud application that allows life sciences companies, CROs, and sites to easily access and exchange information during clinical…
Read More...

Edge Therapeutics, a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that Edge…
Read More...

Regen BioPharma has identified three new series of compounds that activate NR2F6. These compounds are small molecules and were identified using Regen's patented screening methodology…
Read More...

MyoKardia appoints David Meeker, as M.D to the Company’s board of directors. Dr. Meeker is executive VP and head of Sanofi Genzyme, the specialty care global business unit of Sanofi…
Read More...